uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Long-Term Treatment with Pegvisomant as Monotherapy in Patients with Acromegaly: Experience from Acrostudy
Department of Medicine, Columbia University College of Physicians & Surgeons. New York, NY, USA.
Departments of Medicine and Neurosurgery, Allegheny Neuroendocrinology Center, Allegheny General Hospital Pittsburgh, PA, USA.
Pfizer, Collegeville, PA, USA.
Pfizer Health AB, Sollentuna, Sweden.
Show others and affiliations
2015 (English)In: Endocrine Practice, ISSN 1530-891X, Vol. 21, no 3, 264-274 p.Article in journal (Refereed) Published
Abstract [en]

Objective: To evaluate use of pegvisomant, a GH receptor antagonist, as monotherapy in ACROSTUDY, a global safety surveillance study set in 14 countries (373 sites).Methods: A descriptive analysis of safety, magnetic resonance imaging (MRI) reading and treatment outcomes in 710 subjects who received at least one pegvisomant dose as monotherapy during and up to 5 years follow-up in ACROSTUDY.Results: Subjects received 5.4 yr. (mean) of pegvisomant and were followed in ACROSTUDY 3.8 yr. (mean). A total of 1255 adverse events were reported in 345 subjects (48.6%). Serious adverse events were reported in 133 (18.7%) subjects including 22 deaths, none of which were attributed to pegvisomant use. Of 670 (94%) subjects with at least one liver function test reported in ACROSTUDY, 8 (1.2%) had reported increases in transaminases > 3X ULN. No liver failure was reported. Based on central MRI reading, 12 of 542 subjects (2.2%) had a confirmed increase or increase/decrease in tumor size. Injection-site reactions were reported in 2.3%. At 5 years of therapy, IGF-1 level was reported normal in 67.5% (mean dose 17.2 mg/day) and elevated in 29.9% (mean dose 19.8 mg/day). Subjects on 20 mg per day or more rose from 36% at 3 years to 41% at 5 years of therapy.Conclusions: ACROSTUDY data indicate that pegvisomant used as sole medical therapy is safe and effective medical treatment for acromegaly. The reported low incidence of pituitary tumor size increase and liver enzyme elevations are reassuring and support the positive benefit-risk of pegvisomant therapy.

Place, publisher, year, edition, pages
2015. Vol. 21, no 3, 264-274 p.
Keyword [en]
acromegaly, pegvisomant, ACROSTUDY, clinical trial
National Category
Endocrinology and Diabetes
URN: urn:nbn:se:uu:diva-235782DOI: 10.4158/EP14330.ORISI: 000357730800008PubMedID: 25370326OAI: oai:DiVA.org:uu-235782DiVA: diva2:762001
Available from: 2014-11-10 Created: 2014-11-10 Last updated: 2015-08-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Koltowska-Häggström, Maria
By organisation
Department of Women's and Children's Health
In the same journal
Endocrine Practice
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 199 hits
ReferencesLink to record
Permanent link

Direct link